Multi-kinase inhibitor AIV001
Term · Oncology and biomedicine · MLC-T-ONC-015350
A prolonged-release multi-kinase inhibitor, with potential anti-angiogenic, anti-fibrotic and antineoplastic activities. Upon intradermal or intratumoral administration, AIV001 targets and binds to several kinases, including vascular endothelial growth factor receptor (VEGFR), and inhibits multiple pathways involved in neovascularization, fibrosis, abnormal cell proliferation and inflammation. This may reduce dermal neovascularization and fibroplasia during wound healing and scarring, reduce inflammation and fibrosis associated with certain skin conditions, and may reduce neovascularization and cell proliferation associated with certain types of cancers.
| Identifier | MLC-T-ONC-015350 |
|---|---|
| Field | Oncology and biomedicine |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-015350",
"term": "Multi-kinase inhibitor AIV001",
"field": "Oncology and biomedicine",
"definition": "A prolonged-release multi-kinase inhibitor, with potential anti-angiogenic, anti-fibrotic and antineoplastic activities. Upon intradermal or intratumoral administration, AIV001 targets and binds to several kinases, including vascular endothelial growth factor receptor (VEGFR), and inhibits multiple pathways involved in neovascularization, fibrosis, abnormal cell proliferation and inflammation. This may reduce dermal neovascularization and fibroplasia during wound healing and scarring, reduce inflammation and fibrosis associated with certain skin conditions, and may reduce neovascularization and cell proliferation associated with certain types of cancers.",
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/multi-kinase-inhibitor-aiv001/"
}
Record 11,409 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.